...
首页> 外文期刊>Intensive care medicine >Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects.
【24h】

Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects.

机译:大剂量雾化阿米卡星在机械通气健康受试者中的药代动力学。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: Nebulized amikacin may be an attractive option for the treatment of lung infections. Low systemic absorption may permit the use of high doses, leading to high lung concentrations without systemic toxicity. We evaluated the pharmacokinetics and safety of an optimized high-dose amikacin nebulization technique. DESIGN: in vitro and in vivo pharmacokinetic study. PATIENTS AND PARTICIPANTS: Six healthy volunteers (age 21-30 years, weight 49-68[Symbol: see text]kg). INTERVENTIONS: The Aeroneb Pro nebulizer with an Idehaler vertical spacer was evaluated in a bench study. Amikacin was administered intravenously (15[Symbol: see text]mg/kg) and nebulized (40, 50, and 60[Symbol: see text]mg/kg) during noninvasive pressure-support ventilation through a mouthpiece. MEASUREMENTS AND RESULTS: Median (interquartile range) in vitro inhaled fraction was 31% (30-32) and inhalable output was 681[Symbol: see text]mg/h (630-743). Serum concentrations after nebulization were less than or equal to those after infusion. The area under the serum concentration curve was significantly higher after infusion (138[Symbol: see text]mg[Symbol: see text]h(-1)l(-1), 122-143) than after nebulization (49[Symbol: see text]mg[Symbol: see text]h(-1)l(-1), 39-55, at 40[Symbol: see text]mg/kg; 63, 53-67 at 50; 66, 50-71, at 60). Peak serum concentration was also higher after infusion: 48[Symbol: see text]mg/l (45-49) after infusion compared to 8.2 (5.6-8.7), 9.2 (7.6-10.2), and 9.2 (5.2-10.3), respectively. Mean absorption times after nebulization were 2[Symbol: see text]h 24[Symbol: see text]min (2,07-2,45), 2[Symbol: see text]h 21[Symbol: see text]min (2,07-2,35), and 2[Symbol: see text]h 5[Symbol: see text]min (2,00-2,25), respectively. No side effect was observed. CONCLUSIONS: Nebulization of up to 60[Symbol: see text]mg/kg amikacin appears to be safe in healthy subjects and associated with lower serum concentrations than a 15[Symbol: see text]mg/kg infusion.
机译:目的:雾化丁胺卡那霉素可能是治疗肺部感染的一种有吸引力的选择。低的全身吸收可能允许使用高剂量,导致高肺浓度而无全身毒性。我们评估了优化的大剂量阿米卡星雾化技术的药代动力学和安全性。设计:体外和体内药代动力学研究。患者和参与者:六名健康志愿者(年龄21-30岁,体重49-68 [符号:参见文字] kg)。干预措施:在台式研究中评估了带有Idehaler垂直垫片的Aeroneb Pro雾化器。在通过咬嘴进行无创压力支持通气期间,静脉注射阿米卡星(15 [符号:参见文本] mg / kg),并雾化(40、50和60 [符号:参见文本] mg / kg)。测量和结果:体外吸入分数(四分位数范围)为31%(30-32),可吸入量为681 [符号:参见文本] mg / h(630-743)。雾化后的血清浓度小于或等于输注后的浓度。输注后血清浓度曲线下的面积(138 [符号:参见文本] mg [符号:参见文本] h(-1)l(-1),122-143)显着高于雾化后(49 [符号:参见文本] mg [符号:参见文本] h(-1)l(-1),39-55,在40时[符号:参见文本] mg / kg; 63、53-67,在50; 66、50-71 ,at 60)。输注后的血清峰值浓度也更高:输注后为48 [符号:参见文本] mg / l(45-49),而输液后为8.2(5.6-8.7),9.2(7.6-10.2)和9.2(5.2-10.3),分别。雾化后的平均吸收时间为2 [符号:参见文本] h 24 [符号:参见文本] min(2,07-2,45),2 [符号:参见文本] h 21 [符号:参见文本] min(2 ,07-2,35)和2 [符号:参见文本] h 5 [符号:参见文本] min(2,00-2,25)。没有观察到副作用。结论:雾化高达60 [mg / kg]的丁胺卡那霉素在健康受试者中似乎是安全的,并且其血清浓度低于15 [mg / kg]输注。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号